Literature DB >> 29477425

dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.

A Toumazi1, E Comets2, C Alberti3, T Friede4, F Lentz5, N Stallard6, S Zohar1, M Ursino7.   

Abstract

BACKGROUND AND
OBJECTIVE: Dose-finding, aiming at finding the maximum tolerated dose, and pharmacokinetics studies are the first in human studies in the development process of a new pharmacological treatment. In the literature, to date only few attempts have been made to combine pharmacokinetics and dose-finding and to our knowledge no software implementation is generally available. In previous papers, we proposed several Bayesian adaptive pharmacokinetics-based dose-finding designs in small populations. The objective of this work is to implement these dose-finding methods in an R package, called dfpk.
METHODS: All methods were developed in a sequential Bayesian setting and Bayesian parameter estimation is carried out using the rstan package. All available pharmacokinetics and toxicity data are used to suggest the dose of the next cohort with a constraint regarding the probability of toxicity. Stopping rules are also considered for each method. The ggplot2 package is used to create summary plots of toxicities or concentration curves.
RESULTS: For all implemented methods, dfpk provides a function (nextDose) to estimate the probability of efficacy and to suggest the dose to give to the next cohort, and a function to run trial simulations to design a trial (nsim). The sim.data function generates at each dose the toxicity value related to a pharmacokinetic measure of exposure, the AUC, with an underlying pharmacokinetic one compartmental model with linear absorption. It is included as an example since similar data-frames can be generated directly by the user and passed to nsim.
CONCLUSION: The developed user-friendly R package dfpk, available on the CRAN repository, supports the design of innovative dose-finding studies using PK information.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dose-finding; Maximum tolerated dose; Pharmacokinetics; Phase I clinical trials; R package

Mesh:

Year:  2018        PMID: 29477425     DOI: 10.1016/j.cmpb.2018.01.023

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  5 in total

1.  BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data.

Authors:  Barry S Eggleston; Joseph G Ibrahim; Becky McNeil; Diane Catellier
Journal:  J Stat Softw       Date:  2021-11-30       Impact factor: 6.440

2.  Design considerations for early-phase clinical trials of immune-oncology agents.

Authors:  Nolan A Wages; Cody Chiuzan; Katherine S Panageas
Journal:  J Immunother Cancer       Date:  2018-08-22       Impact factor: 13.751

3.  New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment.

Authors:  Francesco De Pretis; Barbara Osimani
Journal:  Int J Environ Res Public Health       Date:  2019-06-24       Impact factor: 3.390

4.  Recognition of Immune Microenvironment Landscape and Immune-Related Prognostic Genes in Breast Cancer.

Authors:  Huiling Wang; Shuo You; Meng Fang; Qian Fang
Journal:  Biomed Res Int       Date:  2020-11-15       Impact factor: 3.411

Review 5.  Recent advances in methodology for clinical trials in small populations: the InSPiRe project.

Authors:  Tim Friede; Martin Posch; Sarah Zohar; Corinne Alberti; Norbert Benda; Emmanuelle Comets; Simon Day; Alex Dmitrienko; Alexandra Graf; Burak Kürsad Günhan; Siew Wan Hee; Frederike Lentz; Jason Madan; Frank Miller; Thomas Ondra; Michael Pearce; Christian Röver; Artemis Toumazi; Steffen Unkel; Moreno Ursino; Gernot Wassmer; Nigel Stallard
Journal:  Orphanet J Rare Dis       Date:  2018-10-25       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.